Bacteriologic and clinical applications of a new extended-spectrum parenteral cephalosporin

American Journal of Medicine

Volumn 100, Issue 6 A, 1996, Pages 45S-51S

  Segreti, John ^a   Levin, Stuart ^a  

^a RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL PNEUMONIA; BACTERIUM ISOLATION; CITROBACTER; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CLEARANCE; DRUG POTENCY; DRUG SAFETY; ENTEROBACTERIACEAE; HOSPITAL INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; ANTIBIOTIC RESISTANCE; BACTERIUM; DRUG ANTAGONISM; DRUG EFFECT; MICROBIOLOGICAL EXAMINATION; REVIEW;

BACTERIA; CEPHALOSPORINS; DRUG RESISTANCE, MICROBIAL; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84911377263     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(96)00107-6     Document Type: Conference Paper

References (56)

1. Grassi GG, Grassi C. Cefepime: overview of activity in vitro and in vivo. J Antimicrob Chemother. 1993;32(suppl B):87-94.
2. Jacoby GA. Genetics of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis. 1994;23(suppl 1):2-11.
3. Jones RN, Kehrberg EN, Erwin ME, Anderson SC, and the Fluoroquinolone Resistance Surveillance Group. Prevalence of important pathogens and antimicrobial activity of parenteral drug at numerous medical centers in the United States. Diagn Microbiol Infect Dis. 1994;19:203-215.
4. Bellido F, Pechere JC, Hancock REW. Novel method for measurement of outer membrane permeability to new β-lactams in intact Enterobacter cloacae cells. Antimicrob Agents Chemother. 1991;35:68-72.
5. Fuchs PC, Jones RN, Barry AL, Thornsberry C. Evaluation of the in vitro activity of BMY-28142, a new broad spectrum cephalosporin. Antimicrob Agents Chemother. 1985;27:679-682.
6. Hiraoka M, Masuyoshi S, Mitsuhashi S. Cephalosporinase interactions and antimicrobial activity of BMY-28142, ceftazidime and cefotaxirne. J Antibiot (Tokyo). 1988;41:86-93.
7. Jones RN, Thornsberry C, Barry AL. In vitro evaluation of HR 810, a new wide-spectrum amino-thiazolyl alpha-methoximino cephalosporin. Antimicrob Agents Chemother. 1984;25:710-718.
8. Nikaido H, Liu W, Rosenberg E. Outer membrane permeability and β-lactamase stability of dipolar ionic cephalosporins containing methoxyimino substituents. Antimicrob Agents Chemother. 1990;34:337-342.
9. Phelps DJ, Carlton DD, Farrell CA, Kessler RE. Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy. Antimicrob Agents Chemother. 1986;29:845-848.
10. Naito T, Aburaki S, Kamachi H, et al. Synthesis and structure-activity relationships of a new series of cephalosporins. BMY-28142 and related compounds. J Antibiot. 1986;39:1092-1107.
11. Gentry LO, Rodriguez-Gomez G. Randomized comparison of cefepime and ceftazidime for treatment of skin, surgical wound, and complicated urinary tract infections in hospitalized subjects. Antimicrob Agents Chemother. 1991;35:2371-2374.
12. Edelstein H, Chirurgi V, Oster S, et al. A randomized trial of cefepime (BMY 28142) and ceftazidime for the treatment of pneumonia. J Antimicrob Chemother. 1991;28:569-575.
13. Clynes N, Scully BE, Neu HC. The use of cefepime (BMY 28142) to treat respiratory infections. Diagn Microbiol Infect Dis. 1989;12:257-260.
14. Barbhaiya RH, Forgue ST, Gleason CR, et al. Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. Antimicrob Agents Chemother. 1990;34:1118-1122.
15. Neu H. The safety profile of cefepime, a new expanded-spectrum cephalosporin. Am J Med. 1993.
16. Giamarellou H. Low-dosage cefepime treatment for serious bacterial infections. J Antimicrob Chemother. 1993;32(suppl B):123-132.
17. Hoepelman AIM, Kieft H, Aoun M, et al. International comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother. 1993;32(suppl B):175-186.
18. Mouton Y, Chidiac C, Humbert G, et al. A noncomparative, multicentre study of cefepime in the treatment of serious bacterial infections. J Antimicrob Chemother. 1993;32(suppl B):133-140.
19. Leophonte P, Bertrand A, Nouvet G, et al. A comparative study of cefepime and ceftazidime in the treatment of community-acquired lower respiratory tract infections. J Antimicrob Chemother. 1993;31(suppl B):165-173.
20. Sanders CC. β-lactamases of Gram-negative bacteria: new challenges for new drugs. Clin Infect Dis. 1992;14:1089-1099.
21. Bellido F, Pechère JC, Hancock REW. Reevaluation of the factors involved in the efficacy of new beta-lactams against Enterobacter cloacae. Antimicrob Agents Chemother. 1991;35:73-78.
22. Pucci MJ, Boice-Sowek J, Kessler RE, Dougherty TJ. Comparison of cefepime, cefpirome, and cefaclidine binding affinities for penicillin-binding proteins in Escherichia coli K-12 and Pseudomonas aeruginosa SC8329. Antimicrob Agents Chemother. 1991;35:2312-2317.
23. Then RL, Angehrn P. Ways to overcome cephalosporinase-mediated β-lactam resistance in Enterobacter cloacae. Chemoterapia. 1985;4:83-89.
24. Neu HC, Chin NX, Jules K, Labthavikul P. The activity of BMY-28142, a new broad spectrum beta-lactamase stable cephalosporin. J Antimicrob Chemother. 1986;17:441-452.
25. Sanders CC, Sanders WE Jr. Type I β-lactamases of gram-negative bacteria: interactions with β-lactam antibiotics. J Infect Dis. 1986;154:792-800.
26. Fung-Tomc J, Huczko E, Pearce M, Kessler RE. Frequency of in vitro resistance of Pseudomonas aeruginosa to cefepime, ceftazidime, and cefotaxime. Antimicrob Agents Chemother. 1988;32:1443-1445.
27. Gradelski E, Fung-Tomc J, Huczko E, Kessler RE. Development of resistance in Pseudomonas aeruginosa to broad-spectrum cephalosporins via stepwise mutations. J Antimicrob Chemother. 1993;32(suppl B):75-80.
28. Vuye A, Pijck J. In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin. Antimicrob Agents Chemother. 1985;27:574-577.
29. Neu HC, Chin NX, Novelli A. In vitro activity of E-1040, a novel cephalosporin with potent activity against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1988;32:1666-1675.
30. Piddock LJV, Griggs DJ. Selection and characterization of cefepime-resistant Gram-negative bacteria. J Antimicrob Chemother. 1991;28:669-676.
31. Fung-Tomc J, Dougherty TJ, DeOrio FJ, Simich-Jacobson V, Kessler RE. Activity of cefepime against ceftazidime- and cefotaxime-resistant Gram-negative bacteria and its relationship to beta-lactamase levels. Antimicrob Agents Chemother. 1989;33:498-502.
32. Jarlier V, Liu W, Nicholas MH, Trias J, Nikaido H. Omp C expression is associated with overproduction of the chromosomal cephalosporinase in Enterobacter cloacae. Conference on Antimicrobial Agents and Chemotherapy, Atlanta, GA. 1990;133. American Society for Microbiology, Washington, DC.
33. Hussain Qadri SM, Veno Y, Almodevar E, Tullo D, Al-Ahdal M. Comparative in vitro evaluation of cefepime, an aminothiazolyl methoxyamino cephem. Drug Invest. 1993;5:127-134.
34. Bodey GP, Ho DH, LeBlanc B. In vitro studies of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985;27:265-269.
35. Tsuji A, Maniatis A, Bertram MA, Young LS. In vitro activity of BMY-28142 in comparison with those of other beta-lactam antimicrobial agents. Antimicrob Agents Chemother. 1985;27:515-519.
36. Visser MR, Hoepelman IM, Beumer H, Rozenberg-Arska M, Verhoef J. Comparative in vitro antibacterial activity of the new carbapenem meropenem (SM-7338). Eur J Clin Microbiol Infect Dis. 1989;8:1061-1064.
37. King A, Boothman C, Phillips L. Comparative in vitro activity of cefpirome and cefepime, two new cephalosporins. Eur J Clin Microbiol Infect Dis. 1990;9:677-685.
38. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibilities of 177 penicillin-susceptible and -resistant pneumococci to FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem, and vancomycin. Antimicrob Agents Chemother. 1994;38:898-900.
39. Yee YC, Thornsberry C, Brown SD, et al. A comparative study of the invitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother. 1993;32:13-19.
40. Rummens JL, Gordts B, Van Landuty HW. In vitro susceptibility of Capnocytophaga species to 29 antimicrobial agents. Antimicrob Agents Chemother. 1986;30:739-742.
41. Berkey P, Moore D, Rolston K. In vitro susceptibilities of Nocardia species to newer antimicrobial agents. Antimicrob Agents Chemother. 1988;32:1078-1079.
42. Cynamon MH, Palmer GS, Sorg TB. Comparative in vitro activities of ampicillin, BMY 28142, and imipenem against Mycobacterium avium complex. Diagn Microbiol Infect Dis. 1987;6:151-155.
43. Rolston KVI, Alvarez ME, Hsu KC, Bodey GP. In vitro activity of cefpirome (HR-810), WIN-49375, BMY-28142 and other antibiotics against nosocomially important isolates from cancer patients. J Antimicrob Chemother. 1986;17:453-457.
44. Bosso JA, Saxon BA, Matsen JM. Comparative activity of cefepime, alone and in combination against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from cystic fibrosis patients. Antimicrob Agents Chemother. 1991;35:783-784.
45. Voutsinas D, Mavroudis T, Avlamis A, Giamarellou H. Comparative in vitro activity of cefepime (BMY-28142) against multiresistant nosocomial isolates of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 1989;8:917-919.
46. Pechère JC, Marchou B, Michea-Hamzehpour M, Auckenthaler R. Emergence of resistance after therapy with antibiotics used alone or combined in a murine model. J Antimicrob Chemother. 1986;17(suppl):11-18.
47. Marchou B, Michea-Hamzehpour M, Lucain C, Pechère JC. Development of β-lactam resistant Enterobacter cloacae in mice. J Infect Dis. 1987;156:369-373.
48. Pechère JC, Vladoianu IR. Development of resistance during ceftazidime and cefepime therapy in a murine peritonitis model. J Antimicrob Chemother. 1992;29:563-573.
49. Barbhaiya RH, Forgue ST, Gleason CR, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother. 1992;36:552-557.
50. Kovarik J, Rozenberg-Arska M, Visser M, Verhoef J. Pharmacodynamics of cefepime. Scand J Infect Dis. 1991;74(suppl):270-273.
51. Pfeffer M, Knupp CA. Safety and dose proportionality study of cefepime in normal healthy male volunteers. Study No. AI411-155-001. Data on file, Bristol-Myers Squibb Pharmaceuticals. Research Institute, Wallingford, CT.
52. Barbhaiya RH, Knupp CA, Pittman KA. Effects of age and gender on pharmacokinetics of cefepime. Antimicrob Agents Chemother. 1992;36:1181-1185.
53. MAXIPIME® Prescribing Information. Data on file, Bristol-Myers Squibb.
54. Tauber MG, Hackbarth CJ, Scott KG, Rusnak MG, Sande MA. New cephalosporins cefotaxime, cefpimizole, BMY 28142, and HR 810 in experimental pneumonococcal meningitis in rabbits. Antimicrob Agents Chemother. 1985;27:340-342.
55. van Ogtrop ML, Guiot HFL, Mattie H, van Furth R. Modulation of the intestinal flora of mice by parenteral treatment with broad-spectrum cephalosporins. Antimicrob Agents Chemother. 1991;35:976-982.
56. Bächer K, Schaeffer M, Lode H, Nord CE, Borner K, Koeppe P. Multiple dose pharmacokinetics, safety, and effects on faecal microflora, of cefepime in healthy volunteers. J Antimicrob Chemother. 1992;30:365-375.